Aβ oligomers trigger and accelerate Aβ seeding.


Journal

Brain pathology (Zurich, Switzerland)
ISSN: 1750-3639
Titre abrégé: Brain Pathol
Pays: Switzerland
ID NLM: 9216781

Informations de publication

Date de publication:
01 2020
Historique:
received: 20 02 2019
accepted: 06 05 2019
pubmed: 18 5 2019
medline: 30 9 2020
entrez: 18 5 2019
Statut: ppublish

Résumé

Aggregation of amyloid-β (Aβ) that leads to the formation of plaques in Alzheimer's disease (AD) occurs through the stepwise formation of oligomers and fibrils. An earlier onset of aggregation is obtained upon intracerebral injection of Aβ-containing brain homogenate into human APP transgenic mice that follows a prion-like seeding mechanism. Immunoprecipitation of these brain extracts with anti-Aβ oligomer antibodies or passive immunization of the recipient animals abrogated the observed seeding activity, although induced Aβ deposition was still evident. Here, we establish that, together with Aβ monomers, Aβ oligomers trigger the initial phase of Aβ seeding and that the depletion of oligomeric Aβ delays the aggregation process, leading to a transient reduction of seed-induced Aβ deposits. This work extends the current knowledge about the role of Aβ oligomers beyond its cytotoxic nature by pointing to a role in the initiation of Aβ aggregation in vivo. We conclude that Aβ oligomers are important for the early initiation phase of the seeding process.

Identifiants

pubmed: 31099449
doi: 10.1111/bpa.12734
pmc: PMC6916291
doi:

Substances chimiques

Amyloid 0
Amyloid beta-Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-45

Informations de copyright

© 2019 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.

Références

J Neurochem. 2002 Apr;81(2):229-36
pubmed: 12064470
Brain. 2014 Nov;137(Pt 11):2909-2915
pubmed: 25212850
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9758-63
pubmed: 23703910
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):4012-7
pubmed: 19228947
Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):111-6
pubmed: 17190811
J Neurosci. 2000 May 15;20(10):3606-11
pubmed: 10804202
Nat Med. 2015 Jul;21(7):802-7
pubmed: 26099047
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Nature. 2013 Sep 5;501(7465):45-51
pubmed: 24005412
Brain Pathol. 2015 Nov;25(6):743-52
pubmed: 25677332
J Neurochem. 2007 Jun;101(5):1172-84
pubmed: 17286590
J Neurochem. 2013 Aug;126(4):473-82
pubmed: 23672786
Nature. 2002 Apr 4;416(6880):535-9
pubmed: 11932745
Cell Rep. 2015 Jun 23;11(11):1760-71
pubmed: 26051935
J Biol Chem. 2010 Jun 4;285(23):17798-810
pubmed: 20348104
PLoS Biol. 2004 Oct;2(10):e321
pubmed: 15383837
Sci Transl Med. 2013 Jul 17;5(194):194re2
pubmed: 23863834
J Neurosci. 2017 Jan 4;37(1):152-163
pubmed: 28053038
Sci Rep. 2015 Mar 23;5:9349
pubmed: 25879692
Science. 2006 Sep 22;313(5794):1781-4
pubmed: 16990547
J Neurosci. 2006 Oct 4;26(40):10129-40
pubmed: 17021169
Science. 2003 Apr 18;300(5618):486-9
pubmed: 12702875
EMBO J. 2018 Jan 17;37(2):167-182
pubmed: 29229786
J Biol Chem. 2006 Feb 17;281(7):4292-9
pubmed: 16361260
Cell. 2016 Feb 11;164(4):603-15
pubmed: 26871627
PLoS One. 2014 Feb 12;9(2):e89014
pubmed: 24533166
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):11025-30
pubmed: 22711819
J Biol Chem. 2008 Jan 11;283(2):677-83
pubmed: 17962197
Mol Neurodegener. 2012 Aug 06;7:37
pubmed: 22866920
Nat Chem Biol. 2011 Jul 31;7(9):602-9
pubmed: 21804535
J Neurosci. 2014 Oct 8;34(41):13629-43
pubmed: 25297091
J Neurosci. 2011 Oct 12;31(41):14488-95
pubmed: 21994365
Acta Neuropathol. 2014 Oct;128(4):477-84
pubmed: 25193240
J Neurosci. 2006 Apr 5;26(14):3821-8
pubmed: 16597736
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13287-92
pubmed: 9371838

Auteurs

Natalie Katzmarski (N)

Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Stephanie Ziegler-Waldkirch (S)

Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Nina Scheffler (N)

Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Christian Witt (C)

Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Claudia Abou-Ajram (C)

Biomedical Center (BMC), Ludwig-Maximilians-University Munich, Munich, Germany.

Brigitte Nuscher (B)

Biomedical Center (BMC), Ludwig-Maximilians-University Munich, Munich, Germany.

Marco Prinz (M)

Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Insitute of Neuropathology, Medical Center - University of Freiburg, Freiburg, Germany.
BIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany.

Christian Haass (C)

Biomedical Center (BMC), Ludwig-Maximilians-University Munich, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Melanie Meyer-Luehmann (M)

Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH